[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Biopharma Credit Plc LSE:BPCR London Ordinary Share GB00BDGKMY29 ORD USD0.01
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 0.98 3,269,831 16:35:04
Bid Price Offer Price High Price Low Price Open Price
0.978 0.982 0.984 0.974 0.98
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Unknown 99.47 79.67 5.80 16.9 1,346
Last Trade Time Trade Type Trade Size Trade Price Currency
16:58:12 O 14,310 0.98115 USD

Biopharma Credit (BPCR) Latest News (1)

More Biopharma Credit News
Biopharma Credit Investors    Biopharma Credit Takeover Rumours

Biopharma Credit (BPCR) Discussions and Chat

Biopharma Credit Forums and Chat

Date Time Title Posts
21/9/202117:28::: BIOPHARMA CREDIT PLC :::68

Add a New Thread

Biopharma Credit (BPCR) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-09-21 15:58:120.9814,31014,040.26O
2021-09-21 15:35:040.9817,92617,567.48UT
2021-09-21 15:23:210.9817,79117,506.34AT
2021-09-21 15:23:210.9817,20916,933.66AT
2021-09-21 15:18:480.984,9174,818.66AT
View all Biopharma Credit trades in real-time

Biopharma Credit (BPCR) Top Chat Posts

DateSubject
21/9/2021
09:20
Biopharma Credit Daily Update: Biopharma Credit Plc is listed in the Unknown sector of the London Stock Exchange with ticker BPCR. The last closing price for Biopharma Credit was US$0.98.
Biopharma Credit Plc has a 4 week average price of US$0.97 and a 12 week average price of US$0.96.
The 1 year high share price is US$1.03 while the 1 year low share price is currently US$0.95.
There are currently 1,373,872,373 shares in issue and the average daily traded volume is 1,532,808 shares. The market capitalisation of Biopharma Credit Plc is £1,346,394,925.54.
21/9/2021
17:28
speedsgh: Net Asset Value(s) and Monthly Factsheet - HTTPS://uk.advfn.com/stock-market/london/biopharma-credit-BPCR/share-news/BioPharma-Credit-PLC-Net-Asset-Values-and-Monthly/86101788 As at the 31 August 2021 the unaudited net asset value per Ordinary Share, including current period revenue, was 99.22 cents. The Company's factsheet will be located on the Company's website, hxxp://bpcruk.com. [31/8/21: 99.22 cents per share] [31/7/21: 100.38 cents per share] [30/6/21: 99.80 cents per share] [31/5/21: 100.93 cents per share] [30/4/21: 100.27 cents per share] [31/3/21: 99.85 cents per share] [28/2/21: 101.40 cents per share] [31/1/21: 100.84 cents per share] [31/12/20: 100.37 cents per share] [30/11/20: 99.91 cents per share] [31/10/20: 101.13 cents per share] [30/9/20: 101.00 cents per share]
20/9/2021
20:24
williamcooper104: For WHT it's not where it's listed but where the tax residency of the parent company who pays the dividend is So for BPCR it's the UK (from memory it's not in the Channel Islands) thus no WHT AY (a renewable yield co) for instance is NYSE listed but tax resident in the UK and thus you get your dividends WHT free (Needless to say I am not a tax advisor - and rules do often change/get interpreted wrongly)
20/9/2021
20:10
tiltonboy: BPCR can be held in an ISA
20/9/2021
20:06
jonwig: roger - it's not a US listing, though its currency is USD. It's moving from the LSE specialist fund segment to the LSE main market. So there's no US withholding tax, but its dividends are all or part payments of interest, rather than share dividends, so the taxation is different. My broker says they can't be held in an ISA (as quoted in USD) but maybe that's just them saying it.
20/9/2021
19:50
rogerramjett: Interested in investing here but wondered with this being a US listing are the dividend subject to withholding tax. I lost out on tax within my ISA when investing in CAC40 listed TotalEnergies and understand that with US traded stocks you can complete a form which reduces tax on dividends. Just not sure if it's applicable to BPCR as its an investment trust. If tax is with held what is this amount please ? Reading the previous post it mentions listing on LSE. Is this going ahead or in the pipeline? I assume this will eliminate any withholding tax concerns which ultimately reduce the yield. Thanks in advance.
15/9/2021
09:32
davebowler: Liberum; Mkt Cap £970m | Share price $0.98 | Prem/(disc) -2.8% | Div yield 7.5% Event BioPharma Credit's NAV per share at 30 June 2021 was 99.8 cents (previously reported), representing a NAV total return of 3.2% over H1. We estimate look-through recurring EPS of 3.7 cents (1.05x dividend cover) and a capital loss of 0.4 cents. The portfolio generated additional liquidity totalling $124m, including pre-payments. This included $97m from payments from the Sebela loan, including a final prepayment premium totalling $1.5m. The final payment was made on 30 June 2021, with BPCR realising an IRR of 11.2% on the investment. During H1, BPCR and BioPharma-V2 agreed a $300m senior secured term loan with LumiraDx, a UK based diagnostics company. LumiraDx is now the second largest loan in the portfolio behind Sarepta ($350m). At the period-end, BPCR's cash balance was $211.3m, representing 15.5% of NAV. Post-period end corporate updates for the BPCR included: Proposed main market listing - an application has been submitted to trade on the premium segment of the LSE. Continuation resolution brought forward - this has been brought forward by a year from the required five year mark to 30 September 2021 and will be held at the forthcoming AGM. RCF refinanced - the committed RCF with JPMorgan Chase has been reduced from $200m to $50m, while allowing for an increase up to $200m. The margin payable under the RCF has reduced from 4.00% to 2.75%. View BPCR has continued to generate a high level of income, despite the impact of cash drag, with credit quality remained materially unaffected by the pandemic. We believe the current 2.8% discount and 7.5% dividend yield are an attractive entry point for a high quality portfolio that has delivered consistent returns since launching in 2017. The recent corporate announcements should positively support sentiment. Life sciences companies will require substantial capital over the coming years, as the number of number of products undergoing clinical trials continues to grow. The manager continues to report a strong pipeline and the focus will be on deploying resources. The loans are typically structured to provide protection against cash drag from repayments in the form of prepayment fees and make-whole penalties. BPCR's origination pipeline is likely to be further supported by the growing need for acquisition financing. Global life sciences M&A volume over H1 totalled $111bn, a 516% increase on H120.
15/9/2021
07:42
speedsgh: Half-yearly Report - HTTPS://www.investegate.co.uk/biopharma-credit-plc--bpcr-/rns/half-yearly-report/202109150700047778L/
20/8/2021
22:12
speedsgh: Net Asset Value(s) - HTTPS://uk.advfn.com/stock-market/london/BPCR/share-news/BioPharma-Credit-PLC-Net-Asset-Values/85885768 As at the 31 July 2021 the unaudited net asset value per Ordinary Share, including current period revenue, was 100.38 cents. The Company's factsheet will be located on the Company's website, hxxp://bpcruk.com [31/7/21: 100.38 cents per share] [30/6/21: 99.80 cents per share] [31/5/21: 100.93 cents per share] [30/4/21: 100.27 cents per share] [31/3/21: 99.85 cents per share] [28/2/21: 101.40 cents per share] [31/1/21: 100.84 cents per share] [31/12/20: 100.37 cents per share] [30/11/20: 99.91 cents per share] [31/10/20: 101.13 cents per share] [30/9/20: 101.00 cents per share]
22/7/2021
07:43
speedsgh: Net Asset Value(s) and Monthly Factsheet - HTTPS://uk.advfn.com/stock-market/london/biopharma-credit-BPCR/share-news/BioPharma-Credit-PLC-Net-Asset-Values-and-Monthly/85638552 As at the 30 June 2021 the unaudited net asset value per Ordinary Share, including current period revenue, was 99.80 cents. The Company's factsheet will be located on the Company's website, hxxp://bpcruk.com. [30/6/21: 99.80 cents per share] [31/5/21: 100.93 cents per share] [30/4/21: 100.27 cents per share] [31/3/21: 99.85 cents per share] [28/2/21: 101.40 cents per share] [31/1/21: 100.84 cents per share] [31/12/20: 100.37 cents per share] [30/11/20: 99.91 cents per share] [31/10/20: 101.13 cents per share] [30/9/20: 101.00 cents per share]
24/5/2021
18:28
speedsgh: Net Asset Value(s) and Monthly Factsheet - HTTPS://uk.advfn.com/stock-market/london/biopharma-credit-BPCR/share-news/BioPharma-Credit-PLC-Net-Asset-Values-and-Monthly/85190709 As at the 30 April 2021 the unaudited net asset value per Ordinary Share, including current period revenue, was 100.27 cents. The Company's factsheet will be located on the Company's website, hxxp://bpcruk.com. [30/4/21: 100.27 cents per share] [31/3/21: 99.85 cents per share] [28/2/21: 101.40 cents per share] [31/1/21: 100.84 cents per share] [31/12/20: 100.37 cents per share] [30/11/20: 99.91 cents per share] [31/10/20: 101.13 cents per share] [30/9/20: 101.00 cents per share]
Biopharma Credit share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
BPCR
Biopharma ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210922 05:16:39